Trading Update

RNS Number : 2209U

Instem plc

24 December 2012

 



24 December 2012

Embargoed for 07:00

Instem plc

("Instem", the "Company" or the "Group")

Trading Update

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global early development healthcare market, today provides an update on trading in the year ending 31 December 2012.

Further to recent announcements, a number of contracts required to meet revenue and profit expectations for the year remain pending. Their ability to contribute to current year results will only be known definitively at the year-end; accordingly Instem now intends to announce its planned trading update in early January.

For further information, please contact:

Instem plc	[phone]
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser & Broker)	[phone]
Aubrey Powell
Joe Stroud
Newgate Threadneedle	[phone]
Caroline Evans-Jones
Fiona Conroy

About Instem plc

Instem is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

Instem has over 130 customers in North America, Europe, China, India and Japan, including 16 of the top 20 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Group employs over 110 people in seven offices in the US, UK, China and India; and has a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software, making Instem an ideal partner to help unlock the scientific/commercial value from these legacy repositories. 

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/

 

END

 

 

TSTLFFSIFILVFIF